EUVIMEDEUVIMED entdecken
Open Access

Children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone treated on Children's Oncology Group studies

Nathan J Schloemer iD, Wei Xue, Amira Qumseya, Leo Y Luo, Susan M Hiniker iD, Timothy B Lautz iD, Daniel S Rhee iD, Michael A Arnold, Rajkumar Venkatramani

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31200 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Nathan J Schloemer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Bone Neoplasms, Rhabdomyosarcoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Children's Oncology Group, NCI NIH HHS, St. Baldrick's Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. Despite bone metastases being present in 5% of patients at diagnosis, there are limited studies examining these outcomes. We sought to define the prognostic factors, clinical courses, and outcomes of children treated on Children's Oncology Group (COG) clinical trials with RMS metastatic to bone at diagnosis.

Methods

We performed a retrospective analysis of patients diagnosed with bone metastatic RMS enrolled on COG RMS clinical trials (D9802, D9803, ARST0431, or ARST08P1) between 1997 and 2013.

Results

RMS metastatic to bone was identified in 154 patients at a median age of 14.9 years at diagnosis. Fifty‐eight percent of patients were male, 90% had metastases at additional sites, 74% had alveolar histology, and extremity was the most common primary site (31%). Eighty‐six percent of patients ( n = 133) received radiation therapy. The 3‐ and 5‐year event‐free survival (EFS) was 15.4% and 14.5%, respectively. The 3‐ and 5‐year overall survival (OS) was 30.4% and 18.0%, respectively. We identified alveolar histology, FOXO1 fusion presence, unfavorable primary location, higher Oberlin score, and lack of radiation as poor prognostic characteristics for both EFS and OS in univariate analysis. Lack of radiation was not significant when excluding patients with events prior to 20 weeks.

Conclusions

This study is the largest analysis of patients with bone metastatic RMS, and defines the poor overall outcomes and negative prognostic factors for these patients. They may be eligible for therapy deintensification for improved quality of life or pursuit of novel treatments/approaches, which are desperately needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone NeoplasmsRhabdomyosarcomaHumansMaleFemaleChildAdolescentRetrospective StudiesChild, PreschoolYoung AdultPrognosisSurvival RateAdultInfantFollow-Up StudiesCombined Modality Therapy

Stichwörter der Autor:innen

bonecancermetastaticoncologypediatricrhabdomyosarcoma

Autor:innen und Institutionen

  • Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Department of Biostatistics, College of Public Health and Health Professions and College of Medicine, University of Florida, Gainesville, Florida, USA.
  • Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Radiation Oncology, Stanford University, Stanford, California, USA.
  • Department of Surgery, Division of Pediatric Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Nathan J Schloemer, Susan M Hiniker, Timothy B Lautz, Daniel S Rhee

Förderung

  • Children's Oncology Group
  • NCI NIH HHS
  • St. Baldrick's Foundation
  • Children’s Oncology Group

Zitieren

APA

Schloemer, N. J., Xue, W., Qumseya, A., Luo, L. Y., Hiniker, S. M., Lautz, T. B., Rhee, D. S., Arnold, M. A., & Venkatramani, R. (2024). Children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone treated on Children's Oncology Group studies. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31200

Vancouver

Schloemer NJ, Xue W, Qumseya A, Luo LY, Hiniker SM, Lautz TB, et al. Children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone treated on Children's Oncology Group studies. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31200

BibTeX
@article{Schloemer2024,
  author = {Schloemer, Nathan J and Xue, Wei and Qumseya, Amira and Luo, Leo Y and Hiniker, Susan M and Lautz, Timothy B and Rhee, Daniel S and Arnold, Michael A and Venkatramani, Rajkumar},
  title = {Children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone treated on Children's Oncology Group studies},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31200}
}
Kostenlos starten →